Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

Fortress Biotech doubled cash reserves but swung to a $7.9M quarterly net loss.

What the company is saying

Fortress Biotech, led by Chairman and CEO Lindsay A. Rosenwald, M.D., presents Q3 2026 as a period of continued execution and strategic progress. The company highlights the full repayment of its $15.0 million Oaktree credit facility, eliminating all parent-level debt and emphasizing a strengthened balance sheet. Fortress frames its pipeline as diversified and advancing, spotlighting the in-licensing of FB-607 for IBS-D, now in Phase 2 trials with top-line data expected in the second half of 2027, and the approval of anselamimab in Japan, which could trigger future milestone payments. The narrative stresses commercial traction at Journey Medical, with 40,000 Emrosi prescriptions and $18.9 million in net product revenue for the quarter, and growing royalty streams from ZYCUBO and UNLOXCYT. Fortress also points to its indirect exposure to the $130 million Series B financing at Crystalys Therapeutics, where its subsidiary Urica is eligible for a 3% royalty on future dotinurad sales. The tone is confident, focusing on long-term value creation and multiple potential catalysts, while downplaying the swing from prior net income to a current net loss.

What the data suggests

The numbers show Fortress Biotech's consolidated cash and cash equivalents rose from $79.4 million at year-end 2025 to $152.2 million at September 30, 2026, an increase of $72.8 million. This includes $114.1 million attributable to Fortress and private subsidiaries, $22.3 million to Journey Medical, $14.3 million to Mustang Bio, and $1.5 million to Avenue Therapeutics. The company fully repaid its $15.0 million Oaktree credit facility, leaving no parent-level debt. Net revenue for Q3 2026 was $19.2 million, up from $17.6 million in Q3 2025, with $18.9 million from marketed dermatology products. Journey Medical reported 40,000 Emrosi prescriptions and $18.9 million in net product revenue, up from $17.0 million a year earlier. Royalty income was modest at $0.2 million from ZYCUBO and $0.1 million from UNLOXCYT. Research and development expenses rose sharply to $1.7 million from $0.2 million, and selling, general and administrative costs increased slightly to $17.8 million. The company posted a consolidated net loss attributable to common stockholders of $(7.9) million, or $(0.23) per share, compared to net income of $3.7 million, or $0.13 per share basic, in Q3 2025. While the balance sheet is stronger and revenues are growing, the shift to a net loss reflects higher expenses and limited near-term impact from pipeline or royalty streams.

Analysis

The announcement provides a thorough and factual update on realised financial results, including revenue, cash, and net loss figures, as well as the repayment of all parent-level debt. These are well-supported by disclosed numerical data. However, a significant portion of the narrative focuses on forward-looking pipeline milestones (e.g., Phase 2 trial data for FB-607 expected in late 2027, potential royalties from dotinurad, and eligibility for milestone payments on anselamimab), none of which are imminent or quantified in terms of near-term financial impact. The $130 million Series B financing for dotinurad is a large capital event, but Fortress's benefit is limited to a future royalty, with no immediate earnings impact. The tone is measured, but the emphasis on 'potential catalysts' and 'long-term value' inflates the perceived near-term opportunity relative to the actual, modest realised progress and the swing to a net loss. The gap between narrative and evidence is most pronounced in the pipeline and milestone claims, which are long-dated and contingent.

Risk flags

• ●Profitability risk is high, as Fortress moved from a $3.7 million net income in Q3 2025 to a $(7.9) million net loss in Q3 2026, driven by increased research and development and selling, general, and administrative expenses. Sustained losses could erode the improved cash position if not reversed.
• ●Pipeline execution risk is material, with key programs such as FB-607 and MB-109 still in clinical development and no near-term data readouts or approvals. The timeline for these assets to generate revenue is long, and success is uncertain.
• ●Royalty and milestone income is contingent and unquantified, with eligibility for payments from dotinurad and anselamimab dependent on future sales and regulatory approvals. There is no guarantee these will materialize or be significant in the near term.
• ●Operational leverage risk is present, as revenue growth is modest relative to rising expenses. If commercial products like Emrosi fail to accelerate growth or if pipeline assets underperform, the company may face further operating losses.
• ●Disclosure risk exists for pipeline and partnership claims, as the company provides limited detail on licensing terms, trial enrollment, or the financial magnitude of expected milestones, making it difficult to assess the true value and timing of these opportunities.

Bottom line

Fortress Biotech has strengthened its liquidity by doubling cash reserves to $152.2 million and eliminating all parent-level debt, but this has not translated into profitability, as the company posted a $(7.9) million net loss for the quarter. Revenue growth is positive but modest, with most of the increase coming from Journey Medical's Emrosi, which generated 40,000 prescriptions and $18.9 million in net product revenue. Royalty streams from ZYCUBO and UNLOXCYT remain small, and potential future income from pipeline assets and milestone payments is speculative, with key catalysts like FB-607 Phase 2 data not expected until late 2027. The company is betting on long-term value from its pipeline and equity holdings, but the near-term financial picture is dominated by rising expenses and operating losses. Investors should focus on whether Fortress can return to profitability and deliver on its pipeline milestones, as the current cash position provides a buffer but not a solution if losses persist. The most important takeaway is that while Fortress is financially stronger, the path to meaningful earnings from its pipeline remains long and uncertain.

Announcement summary

(NASDAQ:FBIO) Fortress Biotech, Inc. announced its financial results and recent corporate highlights for the third quarter ended September 30, 2026. In September 2026, Fortress repaid in full the remaining $15.0 million in outstanding principal under its senior secured credit agreement with Oaktree Fund Administration, LLC, originally a $50.0 million facility entered into in July 2024, resulting in no outstanding parent-level debt. Fortress’ majority-owned subsidiary entered into an exclusive licensing agreement with Cedars-Sinai to develop FB-607, a novel drug for IBS-D, which is currently in a Phase 2 randomized, placebo-controlled trial, with top-line data expected in the second half of 2027. Journey Medical Corporation, a partner company, reported approximately 40,000 prescriptions for Emrosi® in Q3 2026, with net product revenues of $18.9 million for the quarter, up from $17.0 million in Q3 2025. Emrosi® was approved by the FDA in November 2024 and launched commercially in March 2025. Cyprium Therapeutics, Inc. recognized $0.2 million in royalty revenue on net sales of ZYCUBO®, and Fortress recognized $0.1 million in royalty income on net sales of UNLOXCYT™ in Q3 2026. In July 2026, Crystalys Therapeutics announced a $130 million Series B financing to support late-stage clinical development and commercialization of dotinurad, with Fortress’ controlled subsidiary Urica eligible for a 3% royalty on future net sales. Anselamimab (formerly CAEL-101) was approved in Japan in September 2026 for systemic kappa light chain amyloidosis, making Fortress eligible for commercial and regulatory milestone payments. Triplex is in multiple ongoing clinical trials for CMV, and a clinical trial for MB-109 in glioblastoma and astrocytoma is being considered for Q1 2027. As of September 30, 2026, Fortress’ consolidated cash and cash equivalents totaled $152.2 million, up from $79.4 million as of December 31, 2025, with $114.1 million attributable to Fortress and private subsidiaries, $1.5 million to Avenue Therapeutics, $14.3 million to Mustang Bio, and $22.3 million to Journey Medical. Consolidated net revenue for Q3 2026 was $19.2 million, with $18.9 million from marketed dermatology products, compared to $17.6 million and $17.0 million, respectively, in Q3 2025. Research and development expenses were $1.7 million for Q3 2026, up from $0.2 million in Q3 2025. Selling, general and administrative costs were $17.8 million for Q3 2026, compared to $17.4 million in Q3 2025. The consolidated net loss attributable to common stockholders was $(7.9) million, or $(0.23) per share basic and diluted, for Q3 2026, compared to net income of $3.7 million, or $0.13 per share basic and $0.11 per share diluted, for Q3 2025. As of September 30, 2026, total assets were $280,215,000 and total liabilities were $103,194,000. Stockholders’ equity attributed to the company was $159,997,000, with non-controlling interests of $17,024,000, for total stockholders’ equity of $177,021,000.

Disagree with this article?